Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 218 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: naproxen Clear all
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study of Three Medication Regimens for Acute Low Back Pain

NCT01587274
View directory record Official record
Conditions
Acute Low Back Pain
Interventions
Naproxen, Cyclobenzaprine, Oxycodone/ acetaminophen
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

Orphenadrine and Methocarbamol for LBP

NCT02665286
View directory record Official record
Conditions
Low Back Pain
Interventions
Orphenadrine, Methocarbamol, Naproxen, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

NCT00541489
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Hip
Interventions
Naproxcinod, Naproxen, Placebo
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
36
States / cities
Mobile, Alabama • Montgomery, Alabama • Tuscaloosa, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2009 · Synced Sep 3, 2026, 5:51 PM EDT
Terminated Phase 4 Interventional Results available

Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction

NCT01053507
View directory record Official record
Conditions
Post-Traumatic Headache
Interventions
sumatriptan/naproxen sodium, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Springfield, Missouri • Nashville, Tennessee • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effect of Over-the-counter Analgesics on Postoperative Pain

NCT06948513
View directory record Official record
Conditions
Pain Management
Interventions
Naproxen, Acetaminophen (Standard of Care), ibuprofen
Drug
Lead sponsor
Zitelli & Brodland Skin Cancer Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Clairton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 3, 2026, 5:51 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Post Operative Pain Management Through Adductor Canal Block With Bupivacaine for ACL Reconstruction

NCT05161221
View directory record Official record
Conditions
Pain, Postoperative, ACL
Interventions
OxyCODONE 5 mg Oral Tablet, Naproxen 500 Mg, Tylenol Pill, Liposomal bupivacaine, Femoral Nerve Catheter
Drug · Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03161093
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Naproxen, Fasinumab-matching placebo, Naproxen-matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
58
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

NCT02052908
View directory record Official record
Conditions
Lynch Syndrome
Interventions
Laboratory Biomarker Analysis, Naproxen, Placebo Administration
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

NCT00664560
View directory record Official record
Conditions
Osteoarthritis
Interventions
PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treximet Early Intervention Adolescent Migraine

NCT01016678
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Premiere Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain

NCT02268305
View directory record Official record
Conditions
Low Back Pain
Interventions
MSM 1000mg twice a day (6000 mgs), Placebo capsules twice a day
Drug · Other
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

NCT00034853
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
meloxicam oral suspension, naproxen oral suspension
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
29
States / cities
Little Rock, Arkansas • Madera, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

MAST Trial: Multi-modal Analgesic Strategies in Trauma

NCT03472469
View directory record Official record
Conditions
Nonspecific Pain Post Traumatic Injury
Interventions
Acetaminophen IV/PO, Acetaminophen PO, Ketorolac, Celebrex, Naproxen, Tramadol, Pregabalin, Gabapentin, Lidocaine, Opioids, Regional anesthesia
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers

NCT00442208
View directory record Official record
Conditions
Healthy
Interventions
PN 200
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2008 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naproxen Sodium ER Pharmacokinetic Study

NCT00818415
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium ER (BAYH6689), Commercial Naproxen (Aleve, BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation

NCT00750243
View directory record Official record
Conditions
Healthy
Interventions
LT-NS001, Naprosyn®
Drug
Lead sponsor
Logical Therapeutics
Industry
Eligibility
45 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 3, 2026, 5:51 PM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults

NCT04139824
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
Xanthine Oxidase Inhibitor, nonsteroidal anti-inflammatory drug
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 3, 2026, 5:51 PM EDT
Withdrawn Phase 4 Interventional

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

NCT02945839
View directory record Official record
Conditions
Migraine
Interventions
Preventative Medication (PM), Enhanced Usual Care, PMR (progressive muscle relaxation therapy)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea

NCT03448536
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Naproxen Sodium, (Aleve, BAY117031), Acetaminophen (Tylenol Extra Strength)
Drug
Lead sponsor
Bayer
Industry
Eligibility
15 Years to 35 Years · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
8
States / cities
Chandler, Arizona • Scottsdale, Arizona • Pinellas Park, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Naproxen Sodium Extended-Release Actual Use Study

NCT00751400
View directory record Official record
Conditions
Pain
Interventions
Naproxen Sodium ER (BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
24
States / cities
Anaheim, California • Oceanside, California • San Dimas, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 3, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Naproxen Capsules to Treat Dental Pain

NCT01229228
View directory record Official record
Conditions
Dental Pain
Interventions
Naproxen Test, Naprosyn, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 3, 2026, 5:51 PM EDT